Trial · NCT03842189
Results by group948
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 948
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Maternal Participants With Treatment-emergent Adverse Events (TEAEs) | Group 1 (Maternal): 30 mg/kg BLW | 3 | Participants | ||
| Number of Maternal Participants With Treatment-emergent Adverse Events (TEAEs) | Group 2 (Maternal): 30 to 45 mg/kg BLW | 2 | Participants | ||
| Number of Maternal Participants With Treatment-emergent Adverse Events (TEAEs) | Group 3 (Maternal): 45 mg/kg BLW | 4 | Participants | ||
| Number of Maternal Participants With Treatment-emergent Adverse Events (TEAEs) | Group 4 (Maternal): 45 mg/kgTAW | 4 | Participants | ||
| Number of Maternal Participants With Treatment-emergent Adverse Events (TEAEs) | All Maternal Participants | 13 | Participants | ||
| Number of Neonates/Infants With Adverse Events (AEs) | Group 1 (Neonates and Infants): 30 mg/kg BLW | 3 | Participants | ||
| Number of Neonates/Infants With Adverse Events (AEs) | Group 2 (Neonates and Infants): 30 to 45 mg/kg BLW | 2 | Participants | ||
| Number of Neonates/Infants With Adverse Events (AEs) | Group 3 (Neonates and Infants): 45 mg/kg BLW | 4 | Participants | ||
| Number of Neonates/Infants With Adverse Events (AEs) | Group 4 (Neonates and Infants): 45 mg/kg TAW | 3 | Participants | ||
| Number of Neonates/Infants With Adverse Events (AEs) | All Neonates and Infants | 12 | Participants | ||
| Number of Maternal Participants With Treatment-emergent Serious Adverse Events (TESAEs) | Group 1 (Maternal): 30 mg/kg BLW | 2 | Participants | ||
| Number of Maternal Participants With Treatment-emergent Serious Adverse Events (TESAEs) | Group 2 (Maternal): 30 to 45 mg/kg BLW | 0 | Participants | ||
| Number of Maternal Participants With Treatment-emergent Serious Adverse Events (TESAEs) | Group 3 (Maternal): 45 mg/kg BLW | 1 | Participants | ||
| Number of Maternal Participants With Treatment-emergent Serious Adverse Events (TESAEs) | Group 4 (Maternal): 45 mg/kgTAW | 2 | Participants | ||
| Number of Maternal Participants With Treatment-emergent Serious Adverse Events (TESAEs) | All Maternal Participants | 5 | Participants | ||
| Number of Neonates/Infants With Serious Adverse Events (SAEs) | Group 1 (Neonates and Infants): 30 mg/kg BLW | 2 | Participants | ||
| Number of Neonates/Infants With Serious Adverse Events (SAEs) | Group 2 (Neonates and Infants): 30 to 45 mg/kg BLW | 1 | Participants | ||
| Number of Neonates/Infants With Serious Adverse Events (SAEs) | Group 3 (Neonates and Infants): 45 mg/kg BLW | 1 | Participants | ||
| Number of Neonates/Infants With Serious Adverse Events (SAEs) | Group 4 (Neonates and Infants): 45 mg/kg TAW | 2 | Participants | ||
| Number of Neonates/Infants With Serious Adverse Events (SAEs) | All Neonates and Infants | 6 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03842189/results